Form 8-K - Current report:
SEC Accession No. 0001193125-25-035882
Filing Date
2025-02-26
Accepted
2025-02-26 08:06:16
Documents
14
Period of Report
2025-02-26
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d920809d8k.htm   iXBRL 8-K 26469
2 EX-99.1 d920809dex991.htm EX-99.1 65792
  Complete submission text file 0001193125-25-035882.txt   228262

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tsha-20250226.xsd EX-101.SCH 2845
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tsha-20250226_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tsha-20250226_pre.xml EX-101.PRE 11704
16 EXTRACTED XBRL INSTANCE DOCUMENT d920809d8k_htm.xml XML 3767
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39536 | Film No.: 25666238
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)